论文部分内容阅读
目的:评价卡马西平血药浓度变化对癫痫患儿临床疗效的影响,为癫痫患儿的临床治疗提供参考。方法:选取2012年4月—2015年4月收治的癫痫患儿210例作为研究对象,所有患儿均给予卡马西平治疗,治疗后检测患儿卡马西平血药浓度,分析卡马西平血药浓度变化对癫痫患儿临床疗效影响的相关性。结果:所有患儿经卡马西平治疗后的总有效率并不随血药浓度的升高而增加其疗效,但不良反应的发生率是随其血药浓度的上升而上升,其中卡马西平血药浓度处于4.0~8.0μg/m L范围内,治疗癫痫患者的总有效率为最高(67.21%),且不良发生率较低(11.47%)。结论:提高卡马西平血药浓度并不增加其治疗效果,相反易增加不良反应的发生率,因此监测卡马西平血药浓度控制在治疗窗范围内,可获得最理想的疗效和最低的不良反应。
Objective: To evaluate the effect of carbamazepine blood concentration on clinical efficacy in children with epilepsy, and to provide a reference for the clinical treatment of children with epilepsy. Methods: A total of 210 children with epilepsy were enrolled from April 2012 to April 2015. All children were treated with carbamazepine. After treatment, the plasma concentration of carbamazepine in children was measured. The levels of carbamazepine Correlation between the changes of drug concentration and clinical efficacy in children with epilepsy. Results: The total effective rate of all children after carbamazepine treatment did not increase with the increase of blood concentration, but the incidence of adverse reactions increased with the increase of blood concentration, in which carbamazepine The drug concentration in the range of 4.0 ~ 8.0μg / m L, the total effective rate for the treatment of epilepsy was the highest (67.21%), and the incidence of adverse events was low (11.47%). Conclusion: Increasing blood concentration of carbamazepine does not increase the therapeutic effect, but on the contrary, it is easy to increase the incidence of adverse reactions. Therefore, monitoring the plasma concentration of carbamazepine within the therapeutic window can achieve the best effect and the lowest adverse effect reaction.